Supplementary Tables – Real-world treatment of patients with palbociclib for HR+/HER2– advanced/metastatic breast cancer: the Europe IRIS study
dataset
posted on 2021-11-29, 15:17 authored by Taylor & FrancisTaylor & Francis, Katie Mycock, Lin Zhan, Kieran Hart, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra<div>
<table>
<tr>
<td>
<p><b>Supplementary Table S1. </b>Patient inclusion criteria<b> </b></p>
<p><b>Supplementary Table S2. </b>Therapeutic indications for IBRANCE
(palbociclib) in the EU</p>
<p><b>Supplementary Table S3. </b>Patient demographics and clinical
characteristics for the nine individual EU countries<b></b></p>
<p><b>Supplementary Table S4. </b>Palbociclib treatment patterns for the
nine individual EU countries</p>
<p><b>Supplementary Table S5. </b>Response to palbociclib treatment for
the nine individual EU countries</p>
<p>Real-world treatment
of patients with palbociclib for HR+/HER2– advanced/metastatic breast cancer:
the Europe IRIS study</p>
</td>
</tr>
</table>
</div>
